ALSO NOTED: FDA extends YAZ review; Rastetter to retire from Biogen Idec; Tamoxifen may help boys grow taller;and much more...

> Shares of Schering slipped after the Berlin-based company announced that the FDA had extended the review period for its oral contraceptive Yaz. Yaz is a lower-dose version of Yasmin. Report

> Chutes & Ladders: William Rastetter, who helped engineer the merger of Biogen and Idec, is retiring as executive chairman of Biogen Idec. Bruce Ross will become nonexecutive chairman at the beginning of next year. Article

> Pelias, a biotech start-up in Vienna, has plans to investigate new therapies for hospital-acquired infections. Release

> The breast cancer drug tamoxifen may help short boys grow taller. Article

> San Diego-based TargeGen is moving into a much larger facility. Release

> Baltimore-based Osiris Therapeutics says that it has been given the green light to proceed with clinical trials for a new drug to treat digestive disease. Report

> San Diego-based Lpath Therapeutics has completed $6 million in financing and merged with a public company. Release

> Bedford Labs has initiated the recall of one lot of injectable methotraxate. Release

> Arizona's attorney general has filed suit against dozens of drug makers, claiming they defrauded Medicare out of millions of dollars through inflated drug prices. Report

> Cephalon reported that it has reached a settlement with Teva over their patent dispute concerning Provigil. Release

And Finally... A stroke can destroy 32,000 neurons in just one second. Article

Suggested Articles

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.

Harvard University scientists are teaming up with the Guangzhou Institute of Respiratory Disease with a $115 million boost from China.

Moderna shares shot up a massive 18% after-hours last night on the fairly standard news that it was about to start a drug trial.